Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by christianoon Jun 07, 2022 2:09pm

121 Views

Post# 34737741

Intellectual property returned back to the parent company

Hemostemix (HMTXF) had returned the intellectual property and classified data back, which was long overdue from Aspire Health Science and Accudata solutions, the data received was free of manipulation and integrity intact as mentioned by the company officials

https://www.newsfilecorp.com/redirect/VmKbBSxmVP

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China